Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. Th... Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Pluristem Therapeutics Inc. Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Mehr anzeigen
HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various...
HAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for...
HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based...
The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.19 | -4.30839002268 | 4.41 | 4.55 | 4.1516 | 4695 | 4.37207614 | CS |
| 4 | -0.15 | -3.43249427918 | 4.37 | 4.73 | 4.07 | 8163 | 4.45357719 | CS |
| 12 | -0.25 | -5.59284116331 | 4.47 | 6.14 | 4.07 | 24932 | 5.09979286 | CS |
| 26 | -1.33 | -23.963963964 | 5.55 | 6.18 | 4.07 | 17345 | 5.14905075 | CS |
| 52 | -0.172 | -3.91621129326 | 4.392 | 8.48 | 4.07 | 41220 | 6.03370065 | CS |
| 156 | -3.78 | -47.25 | 8 | 11.5784 | 3.4488 | 56326 | 6.38361145 | CS |
| 260 | -3.78 | -47.25 | 8 | 11.5784 | 3.4488 | 56326 | 6.38361145 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
